The relevance of xCT function in chemoresistance and cell death inhibition, namely, through ferroptosis, is already set in NSCLC [92,93], and our study is in accordance with this, reinforcing that xCT blockade can be a useful adjuvant therapy to improve the efficacy of conventional cancer therapy. The gene discussed is SLC7A11; the disease is cancer.